Clinical trials: Anti-Infective Agents
Sepsis, Shock, Septic
Medical Education for Sepsis Source Control and Antibiotics
Patients with severe sepsis or septic shock suffer from life-threatening infections. Fast and adequate therapy with antibiotics is crucial for survival.
- Trial name
- MEDUSA (NCT01187134)
- Testing
- Change Management
- Where
- 42 sites in Germany
- Volunteers
- 4,138 people
- Sponsor
- Center for Sepsis Control and Care, Germany
Infection
Antimicrobial PK in Infants With Suspected or Confirmed Infection
The purpose of this protocol is to provide a mechanism for the ongoing collection of blood and urine samples in newborns that will be used to measure levels of antimicrobial products used in the newborn population where there are…
- Trial name
- NCT00491426
- Testing
- Ampicillin, Metronidazole, Piperacillin/Tazobactam
- Where
- 6 sites in United States
- Volunteers
- 450 people
- Sponsor
- Duke University
Obesity, Nutrition Disorders
Drug Concentration Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers
The purpose of this study is to assess the drug concentration of Micafungin amongst healthy volunteers having different weight groups.
- Conditions
- Obesity, Nutrition Disorders, Overweight
- Trial name
- Micafungin (NCT01090141)
- Testing
- Micafungin
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Infection
DetermInants of Antimicrobial Use aNd De-escalAtion in Critical Care (DIANA)
DetermInants of Antimicrobial use aNd de-escalAtion in critical care (DIANA study), is a multicenter, international, prospective, observational cohort study, aiming to describe the rate of de-escalation as well as the associated…
- Trial name
- DIANA (NCT02920463)
- Where
- Belgium
- Volunteers
- 1,495 people
- Sponsor
- University Hospital, Ghent
Patient Receiving Anti-infectives Whatever Disease
Population Pharmacokinetics of Anti-infectives in Hospitalized Patients
In case of sepsis, the therapeutic success is strongly influenced by the choice of anti-infectives (AI) in terms of spectrum, dosage and administration schedule.
- Trial name
- OptiPOP (NCT02998411)
- Testing
- Titration
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Catheter-related Bloodstream Infection (CRBSI) Nos
Clinical Trial Comparing Catheter Lock Solutions TaurolockTMHep 100 and Heparin 100 IE/ml.
The purpose of the investigation is to compare two catheter lock solutions (TaurolockTMHep100 and Heparin 100 IE/ml), on the occurence of catheter related blood stream infection, in patients with intestinal failure and a central…
- Trial name
- NCT01948245
- Testing
- TaurolockTMHep100, Heparin 100 IE/ml
- Where
- Denmark
- Volunteers
- 42 people
- Sponsor
- Palle Bekker Jeppesen
Communicable Diseases
Computerized Antibiotic Stewardship Study
Prescribing antibiotics frequently poses problems in practice, since patients don't always receive the right dosage of the right antibiotic for the right period of time.
- Trial name
- COMPASS (NCT03120975)
- Testing
- Computerized decision support and audit & feedback, Audit & Feedback, Standard antibiotic stewardship
- Where
- 3 sites in Switzerland
- Volunteers
- 16,176 people
- Sponsor
- Benedikt Huttner
Nosocomial Pneumonia (NP), Ventilator-associated Pneumonia (VAP)
A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia
The purpose of the study is to evaluate the effects of Ceftazidime-Avibactam compared to Meropenem for treating hospitalized adults with nosocomial pneumonia including ventilator-associated pneumonia
- Trial name
- NCT01808092
- Testing
- ceftazidim-avibactam (CAZ-AVI, experimental product), meropenem (active comparator)
- Where
- 123 sites in Argentina, Brazil and 24 more
- Volunteers
- 969 people
- Sponsor
- Pfizer
Surgery, Central Line Associated Blood Stream Infections (CLABSI)
BIP CVC Clinical Safety and Performance Study
The primary objective of this trial was to determine Bactiguard coated BIP CVC's safety and performance and compare it to corresponding standard uncoated CVC.
- Trial name
- NCT02811380
- Testing
- BIP CVC, Uncoated Standard CVC
- Where
- Sweden
- Volunteers
- 36 people
- Sponsor
- Bactiguard AB
Pulmonary Non-tuberculous Mycobacterial Lung Disease
Inhaled Amikacin Treatment for Nontuberculous Mycobacterial Lung Disease
The incidence of chronic pulmonary disease caused by nontuberculous mycobacteria (NTM) in human immunodeficiency virus (HIV)-negative patients has been increasing worldwide.
- Trial name
- NCT01528930
- Testing
- Amikacin
- Where
- South Korea
- Sponsor
- Samsung Medical Center
Anti-Infective Agents
Compliance of Initial Empiric Antimicrobial Therapy
Hospital infections comprise about half of all undesirable complications related to hospital treatment. In case of bacterial infection administration of antimicrobial agent is a therapy of choice.
- Trial name
- NCT04448665
- Testing
- microbiological investigation
- Where
- Poland
- Volunteers
- 267 people
- Sponsor
- Military Institute od Medicine National Research Institute
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam compared to Doripenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis
- Trial name
- NCT01599806
- Testing
- Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
- Where
- 57 sites in United States, Argentina and 15 more
- Volunteers
- 641 people
- Sponsor
- Pfizer
Catheter Related Infections, Short Bowel Syndrome
Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With Short Bowel Syndrome
This study is designed to determine if the use of 70% ethanol lock solution in central lines decreases the rate of central line infections in children with short bowel syndrome.
- Trial name
- NCT01263574
- Testing
- 70% ethanol
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Pneumonia, Bacterial
Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization
To demonstrate the safety and efficacy of adjunctive therapy with the Amikacin Fosfomycin Inhalation System (AFIS) versus aerosolized placebo in mechanically ventilated patients with Gram-negative and / or Gram-positive bacterial…
- Trial name
- NCT02218359
- Testing
- Amikacin Fosfomycin Inhalation Solution
- Sponsor
- Cardeas Pharma
Anti-Bacterial Agents
Carbapenems De-escalation as Antimicrobial Stewardship
Early de-escalation of carbapenems can reduce unnecessary use of carbaepenems compared with late de-escalation without compromised clinical outcomes
- Trial name
- NCT03114358
- Testing
- Early Carbapenem de-escalation
- Volunteers
- 104 people
- Sponsor
- Chiang Mai University
Neonatal Sepsis, Neutropenia
G-CSF In Neonatal Sepsis With Neutropenia
This study will evaluate whether adding G-CSF to standard treatment improves outcomes in newborns (0-28 days) with sepsis and neutropenia.
- Trial name
- NCT07888829
- Testing
- Granulocyte-colony stimulating factor (G-CSF), Standard Sepsis Management
- Where
- Pakistan
- Volunteers
- 52 people
- Sponsor
- University of Health Sciences Lahore
COVID, Pneumonia, Viral
Anti Infective Agents Impact in COVID-19 Pneumonia
During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et al.
- Trial name
- AZITHROVID (NCT04453501)
- Testing
- favorable outcome
- Where
- France
- Volunteers
- 132 people
- Sponsor
- Centre d'Investigation Clinique et Technologique 805
HIV Infections
Safety and Tolerability of the Vaginal Gel PRO 2000/5
The purpose of this study is to determine whether the vaginal gel PRO 2000/5 causes irritation when used daily. Studies have shown PRO 2000/5 is safe and well tolerated as a vaginal gel in healthy women who are not sexually…
- Trial name
- NCT00006207
- Testing
- PRO 2000
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Urinary Tract Infections, Pyelonephritis
Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
The purpose of this study is to evaluate the efficacy, safety and tolerability of adding 125 mg or 250 mg doses of MK-7655 (relebactam) to imipenem/cilastatin in adults 18 years or older with complicated urinary tract infection…
- Trial name
- NCT01505634
- Testing
- Relebactam 250 mg, Relebactam 125 mg, imipenem/cilastatin 500 mg
- Volunteers
- 302 people
- Sponsor
- Merck Sharp & Dohme LLC
Tuberculous Meningitis
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
The purpose of this study is to compare a 6-month regimen of high-dose rifampicin (RIF), high-dose isoniazid (INH), linezolid (LZD), and pyrazinamide (PZA) versus the World Health Organization (WHO) standard of care (SOC)…
- Trial name
- NCT05383742
- Testing
- Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD)
- Where
- 18 sites in Brazil, India and 10 more
- Volunteers
- 330 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)